Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $243
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $357 to $243.
Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $357 to $243.